

**TECENTRIQ® Vials (840 mg/14 ml)**
Version  
1.2Revision Date:  
11-07-2022Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017**SECTION 1. IDENTIFICATION**

Product name : TECENTRIQ® Vials (840 mg/14 ml)

Product code : RO554-1267/F05

**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone number : US Chemtrec phone (800)-424-9300

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Not a hazardous substance or mixture.

**GHS label elements**

Not a hazardous substance or mixture.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Atezolizumab	1380723-44-3	6.0
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	4.11
L-Histidine	71-00-1	0.31
Acetic acid	64-19-7	0.08
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.04
Water	7732-18-5	> 89.0

**TECENTRIQ® Vials (840 mg/14 ml)**

Version  
 1.2

Revision Date:  
 11-07-2022

Date of last issue: 01-28-2020  
 Date of first issue: 06-10-2017

**SECTION 4. FIRST AID MEASURES**

- General advice : Do not leave the victim unattended.
  
- If inhaled : Move to fresh air.  
 If unconscious, place in recovery position and seek medical advice.  
 If symptoms persist, call a physician.
  
- In case of skin contact : If on skin, rinse well with water.
  
- In case of eye contact : Immediately flush eye(s) with plenty of water.  
 Remove contact lenses.  
 Protect unharmed eye.  
 If eye irritation persists, consult a specialist.
  
- If swallowed : Keep respiratory tract clear.  
 Do not give milk or alcoholic beverages.  
 Never give anything by mouth to an unconscious person.  
 If symptoms persist, call a physician.  
 Rinse mouth with water.
  
- Most important symptoms and effects, both acute and delayed : None known.
  
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
  
- Specific hazards during fire fighting : No information available.
  
- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:  
 Carbon monoxide  
 Nitrogen oxides (NOx)
  
- Further information : Standard procedure for chemical fires.  
 Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
  
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protection : Refer to protective measures listed in sections 7 and 8.

**TECENTRIQ® Vials (840 mg/14 ml)**
Version  
1.2Revision Date:  
11-07-2022Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

tive equipment and emergency procedures

Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).  
Keep in suitable, closed containers for disposal.

---

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass, Vials

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**
**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Atezolizumab	1380723-44-3	IOEL	0.220 mg/m <sup>3</sup>	Roche Industrial Hygiene Committee (RIHC)
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m <sup>3</sup>	NIOSH REL
		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (respir-	5 mg/m <sup>3</sup>	OSHA Z-1

**TECENTRIQ® Vials (840 mg/14 ml)**

Version  
1.2

Revision Date:  
11-07-2022

Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

		able fraction)		
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0

**Engineering measures** : No data available

**Personal protective equipment**

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

In case of contact through splashing:  
 Material : Nitrile rubber  
 Break through time : > 30 min  
 Glove thickness : > 0.11 mm

In case of full contact:  
 Material : butyl-rubber  
 Break through time : > 480 min  
 Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : Aqueous solution, Clear liquid, Sterile liquid

Color : colorless, light yellow

Odor : No data available

Odor Threshold : No data available

pH : 5.8

Melting point/range : No data available

Boiling point/boiling range : No data available

Evaporation rate : No data available

**TECENTRIQ® Vials (840 mg/14 ml)**Version  
1.2Revision Date:  
11-07-2022Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

Self-ignition	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	1.1 g/cm <sup>3</sup> (68 °F / 20 °C)
Solubility(ies)		
Water solubility	:	completely miscible
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions.  Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution
Possibility of hazardous reactions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.
Conditions to avoid	:	No data available
Incompatible materials	:	No data available

**TECENTRIQ® Vials (840 mg/14 ml)**Version  
1.2Revision Date:  
11-07-2022Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017Hazardous decomposition : No data available  
products**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified based on available information.

**Components:****Atezolizumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Acute oral toxicity : LD50 Oral (Rat): 29,700 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative**Carcinogenicity**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**TECENTRIQ® Vials (840 mg/14 ml)**Version  
1.2Revision Date:  
11-07-2022Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Atezolizumab:**

Effects on fetal development : Species: Humans  
Result: Critical exposure in human after parenteral administration only

Species: Humans  
Result: Parenteral administration to pregnant women can cause fetal harm

**STOT-single exposure**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**STOT-repeated exposure**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Aspiration toxicity**

Not classified based on available information.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

No data available

**Further information****Components:****Atezolizumab:**

Remarks : Globular proteins are generally well biodegradable

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : Health injuries are not known or expected under normal use.

**TECENTRIQ® Vials (840 mg/14 ml)**Version  
1.2Revision Date:  
11-07-2022Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Persistence and degradability****Components:****Atezolizumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Bioaccumulative potential****Components:****Atezolizumab:**

Partition coefficient: n-octanol/water : Remarks: No data available

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Partition coefficient: n-octanol/water : log Pow: -3.7 (68 °F / 20 °C)

**Mobility in soil**

No data available

**Other adverse effects****Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).**Components:****Atezolizumab:**



## TECENTRIQ® Vials (840 mg/14 ml)

Version  
1.2

Revision Date:  
11-07-2022

Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

---

### SECTION 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
Do not re-use empty containers.

---

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

Not regulated as a dangerous good

##### IATA-DGR

Not regulated as a dangerous good

##### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

#### Domestic regulation

##### 49 CFR

Not regulated as a dangerous good

#### Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

---

### SECTION 15. REGULATORY INFORMATION

#### CERCLA Reportable Quantity

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

#### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

#### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : No SARA Hazards

**TECENTRIQ® Vials (840 mg/14 ml)**Version  
1.2Revision Date:  
11-07-2022Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Acetic acid	64-19-7	>= 0 - < 0.1 %
-------------	---------	----------------

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Acetic acid	64-19-7	>= 0 - < 0.1 %
-------------	---------	----------------

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations****Massachusetts Right To Know**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1
---	---------

**Pennsylvania Right To Know**

Water	7732-18-5
Atezolizumab	1380723-44-3
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1
Acetic acid	64-19-7

**Maine Chemicals of High Concern**

Product does not contain any listed chemicals

**Vermont Chemicals of High Concern**

Product does not contain any listed chemicals

**Washington Chemicals of High Concern**

Product does not contain any listed chemicals

**California Permissible Exposure Limits for Chemical Contaminants**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1
---	---------

**The ingredients of this product are reported in the following inventories:**

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Atezolizumab

NZIoC : On the inventory, or in compliance with the inventory

**TECENTRIQ® Vials (840 mg/14 ml)**

Version  
1.2

Revision Date:  
11-07-2022

Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory
- IECSC : Not in compliance with the inventory
- TCSI : Not in compliance with the inventory
- TSCA : Product contains substance(s) not listed on TSCA inventory.
- TECI : Not in compliance with the inventory


**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

**SECTION 16. OTHER INFORMATION**

**NFPA 704:**



**HMIS® IV:**

<b>HEALTH</b>	/	0
<b>FLAMMABILITY</b>		0
<b>PHYSICAL HAZARD</b>		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

- ACGIH : USA. ACGIH Threshold Limit Values (TLV)
- NIOSH REL : USA. NIOSH Recommended Exposure Limits
- OSHA P0 : USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
- OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
- ACGIH / TWA : 8-hour, time-weighted average

**TECENTRIQ® Vials (840 mg/14 ml)**

Version 1.2                      Revision Date: 11-07-2022                      Date of last issue: 01-28-2020  
Date of first issue: 06-10-2017

NIOSH REL / TWA                      : Time-weighted average concentration for up to a 10-hour  
workday during a 40-hour workweek  
OSHA P0 / TWA                      : 8-hour time weighted average  
OSHA Z-1 / TWA                      : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date                      : 11-07-2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2104